...their joint venture, Archigen Biotech, citing lack of commercial viability. Archigen's primary project was developing SAIT101, a biosimilar to Biogen's Rituxan. The drug was currently in phase III trials for the treatment of follicular lymphoma. Under the pharmacy benefit, Rituxan currently holds preferred status for 4% of covered lives for the treatment of follicular lymphoma.
SOURCE: MMIT Analytics, as of 11/23/20
No comments:
Post a Comment